Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism

Details for Australian Patent Application No. 2005210221 (hide)

International Classifications

Event Publications

17 August 2006 PCT application entered the National Phase

PCT publication WO2005/075023 Priority application(s): WO2005/075023

19 April 2007 Change of Name(s) of Applicant(s), Section 104

Gessellschaft fur Biotechnologische Forschung mbH (GBF); Institut De La Sante Et De La Recherche Medicale (INSERM); Commissariat A L'energie Atomique The name of the applicant has been changed to Gessellschaft fur Biotechnologische Forschung mbH (GBF); Institut National De La Sante Et De La Recherche Medicale (INSERM); Commissariat A L'energie Atomique (CEA)

9 July 2009 Alteration of Name

The name of the applicant has been altered to Institut National De La Sante Et De La Recherche Medicale (INSERM); Commissariat A L'energie Atomique (CEA); Helmholtz Zentrum fur Infektionsforschung GmbH

7 October 2010 Application Accepted

Published as AU-B-2005210221

3 February 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.